Trial Profile
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Belinostat (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors Acrotech Biopharma; Spectrum Pharmaceuticals
- 12 Nov 2018 Status changed from recruiting to discontinued due to Close out study without completion of Cohort D; Severe Impairment.
- 16 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.